AbbVie and RemeGen Forge Deal for Innovative Bispecific Antibody Targeting Solid Tumors AbbVie and RemeGen have signed an exclusive licensing deal to develop RC148, a groundbreaking bispecific antibody, targeting advanced solid tumors, enhancing cancer immunotherapy.

AbbVie and RemeGen Forge Deal for Innovative Bispecific Antibody Targeting Solid Tumors #United_States #AbbVie #North_Chicago #RemeGen #RC148

FDA Approves RemeGen's Bispecific Antibody RC148 for Phase II Trials in the US RemeGen's bispecific antibody, RC148, has received FDA approval to enter Phase II clinical trials in the United States. This marks a significant achievement in cancer treatment.

FDA Approves RemeGen's Bispecific Antibody RC148 for Phase II Trials in the US #China #FDA_Approval #Yantai #RemeGen #RC148